Analyser av Sprint Bioscience

Sprint Bioscience: Positive pre-clinical data from VRK1 program - Redeye

Redeye comments on Sprint Bioscience's announcement of positive preclinical proof-of-concept data for the VRK1 program.

Redeye • 17 mar 13:27

Sprint Bioscience (Q4 Review): Promising development - Redeye

Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report.

Redeye • 13 feb 10:55

Sprint Bioscience (Q3 review): Gilead deal a strong confirmation - Redeye

Redeye returns with an update on Sprint Bioscience following recent events and the Q3 report.

Redeye • 04 dec 2025 10:19

Sprint Bioscience: Sells TREX1 program to Gilead - Redeye

Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, including an upfront of USD14m, which sho...

Redeye • 24 nov 2025 11:05

Sprint Bioscience: A clear objective to secure a new partner - Redeye

With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively promote and advance its pipeline of candida...

Redeye • 08 sep 2025 11:29

Sprint Biopharma: A clear objective to secure a new partner - Redeye

With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively promote and advance its pipeline of candida...

Redeye • 04 sep 2025 08:40

Sprint Bioscience Q2: Lean with a clear objective to secure a new partner - Redeye

With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively promote and advance its pipeline of candida...

Redeye • 27 aug 2025 09:39

Sprint Bioscience: Collaborates to expand its MASH inflammation programme - Redeye

Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore regarding the thera...

Redeye • 23 jun 2025 08:45

Sprint Bioscience: Increased pressure ahead of the next sprint baton-exchange - Redeye

So far, 2025 has turned out to be a very intense period, including a SEK 23m fundraising, publications, a strategic review, the announced di...

Redeye • 30 maj 2025 08:36

Sprint Bioscience Q1: A highly intense period - Redeye

2025 has turned out to be a very intense period so far, including a SEK 23m fundraising, publications, a strategic review, the announced dis...

Redeye • 27 maj 2025 08:59

Sprint Bioscience: Day One discontinues the VRK1 program - Redeye

During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue the license and the collaboration with S...

Redeye • 12 maj 2025 08:57

Sprint Bioscience: Adding funds and new opportunities - Redeye

Sprint Bioscience has secured 73.9% of a proposed SEK 31.

Redeye • 17 mar 2025 08:19

Sprint Bioscience Q4: Confident expansion - Redeye

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.

Redeye • 13 feb 2025 11:26

Sprint Bioscience: Confident expansion - Redeye

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.

Redeye • 12 feb 2025 12:39

Sprint Bioscience Q3: Steady sales and continued progress - Redeye

Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.

Redeye • 31 okt 2024 10:25

Sprint Bioscience: Steady sales and continued progress - Redeye

Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.

Redeye • 30 okt 2024 10:20

Sprint Bioscience Update: Robust sales and project activity - Redeye

Sprint Bioscience has Q2 sales of SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.

Redeye • 30 aug 2024 08:00

Sprint BioScience Q2: Continuing robust sales and activity - Redeye

Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.

Redeye • 28 aug 2024 09:37

Sprint Bioscience: Improved sales and activity - Redeye

Sprint Bioscience recorded sales improved to SEK 17.

Redeye • 10 maj 2024 12:10

Sprint Bioscience Q1: Improved sales and activity - Redeye

Recorded sales improved to SEK 17.9m (10.9m in Q4 and SEK 0m in Q1 2023), and the cash balance was SEK 39.

Redeye • 08 maj 2024 09:38

Sprint Bioscience: Additional support for the DISA program and the TREX1 potential - Redeye

The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the effect of immuno-oncology therapy, radiat...

Redeye • 12 apr 2024 12:59

Sprint Bioscience Q4 2023: A major step towards break-even - Redeye

Sprint Bioscience recorded sales improved to SEK 10.

Redeye • 15 feb 2024 08:37

Sprint Bioscience: VADA (VRK1) progress support improved sales - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q4 report.

Redeye • 14 feb 2024 10:03

Sprint Bioscience: Replacing Decipher as a VPS34 partner - Redeye

Sprint Bioscience is looking to replace Decipher as a partner for VPS34 as soon as the project is handed back.

Redeye • 02 jan 2024 09:03

Sprint Bioscience: Negativ överraskning - Redeye

Sprint Bioscience (Sprint) meddelar att Deciphera har valt att returnera VPS34-hämmarprogrammet utan att ge något specifikt förtydligande.

Redeye • 18 dec 2023 10:44

Sprint Bioscience: Easing pressure and a sharper focus on value drivers - Redeye

Redeye reviews the Sprint Bioscience case following a change of analyst and provide a more in-depth take on the company’s recent VADA deal.

Redeye • 20 nov 2023 07:45

Sprint Q3: VADA progress and a new CEO - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q3 report.

Redeye • 25 okt 2023 09:35

Sprint Bioscience: New beginnings - Redeye

Redeye reviews the Sprint Bioscience case following a change of analyst and provide a more in-depth take on the company’s recent VADA deal.

Redeye • 13 sep 2023 08:55

Sprint Bioscience Q2: Brief comment on the report - Redeye

Redeye provides a brief comment on Sprint Bioscience’s Q2 report.

Redeye • 24 aug 2023 08:30

Sprint Bioscience: Sprint Bioscience enters a VADA licensing agreement - Redeye

Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharm...

Redeye • 17 aug 2023 08:24

Sprint Bioscience: NASH returns to in-house portfolio - Redeye

Redeye adjusts its estimates for the return of NASH to Sprint Bioscience.

Redeye • 02 jun 2023 13:45

Sprint Bioscience: Misery loves company - Redeye

Redeye is disappointed to learn that Sprint Bioscience will receive back the NASH program from LG Chem.

Redeye • 31 maj 2023 07:34

Sprint Bioscience Q1 2023: VADA deal needed - Redeye

Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near futu...

Redeye • 11 maj 2023 10:34

Sprint Bioscience Q1 2023: VADA deal needed - Redeye

Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near futu...

Redeye • 11 maj 2023 07:31

Sprint Bioscience Q4 2022: Temporary setbacks - Redeye

Redeye comments on Sprint Bioscience’s Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project ...

Redeye • 16 feb 2023 07:04

Sprint Bioscience: ProView; Patent & intellectual property - Redeye

In this episode, we are joined by Jessica Martinsson, COO of Sprint Bioscience, alongside European patent attorneys Joanna Applequist and Mi...

Redeye • 30 dec 2022 08:16

Sprint Bioscience: Hibercell returns PETRA01 to Sprint - Redeye

Redeye is disappointed to learn that Sprint’s former partner, Hibercell, returned the PETRA01 project to Sprint.

Redeye • 21 nov 2022 10:23

Sprint Bioscience Q3 2022: Seal the deal - Redeye

Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project ...

Redeye • 26 okt 2022 14:46

Sprint Bioscience: Announces rights issue - Redeye

Redeye comments on Sprint Bioscience announcing a rights issue.

Redeye • 22 sep 2022 14:01

Sprint Bioscience Q2 2022: Several potential catalysts on the horizon - Redeye

Redeye comments on Sprint’s Q2 2022 report, which aligned with our expectations.

Redeye • 24 aug 2022 15:44

Sprint Bioscience Q1 2022: NIMA launch in June - Redeye

Redeye comments on Sprint’s Q1 2022 report, with the company recently announcing the target and launch date for its internal NIMA project.

Redeye • 11 maj 2022 13:03

Sprint Bioscience: Our Q4 comment - Redeye

Redeye comments on Sprint’s Q4 2021 report, representing a relatively calm quarter on the news front.

Redeye • 16 feb 2022 13:34